Author:
Grados Marco A.,Rizwan Bushra
Publisher
Springer International Publishing
Reference57 articles.
1. Abdallah, C. G., Coplan, J. D., Jackowski, A., Sato, J. R., Mao, X., Shungu, D. C., & Mathew, S. J. (2013). A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 23(4), 276–284.
2. Amaral, O. B., & Roesler, R. (2008). Targeting the NMDA receptor for fear-related disorders. Recent Patents on CNS Drug Discovery, 3, 166–178.
3. Bovasso, G. (2001). The long-term treatment outcomes of depression and anxiety comorbid with substance abuse. Journal of Behavioral Health Service & Research, 28, 42–57.
4. Brady, K. T., Sonne, S. C., & Roberts, J. M. (1995). Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Journal of Clinical Psychiatry, 56, 502–505.
5. Bromet, E., Sonnega, A., & Kessler, R. C. (1998). Risk factors for DSM-III-R posttraumatic stress disorder: Findings from the National Comorbidity Survey. American Journal of Epidemiology, 147, 353–361.